Gentronix looks to Japan
UK biotechnology company Gentronix has entered into a new agreement with LSG Corporation, of Tokyo, Japan. The deal enables introduction of the GreenScreen HC range of human cell-based genotoxicity assays across Japan, allowing scientists to accelerate the pace of drug discovery and development.
UK biotechnology company Gentronix has entered into a new agreement with LSG Corporation, of Tokyo, Japan. The deal enables introduction of the GreenScreen HC range of human cell-based genotoxicity assays across Japan, allowing scientists to accelerate the pace of drug discovery and development.
LSG has more than 30 years" experience in providing researchers with the tools and products required to solve tough challenges within the life science arena. As a subsidiary of EPS Co., Ltd, one of the largest clinical research organisations in Japan, LSG is well placed to promote GreenScreen assays in this key market.
GreenScreen HC, also available with a standardised S9 metabolic activation protocol, identifies genotoxic compounds in early screening of drug candidates. With a microplate format to enable high-throughput analysis, GreenScreen helps to remove the current bottlenecks commonly found in preclinical r&d.
"LSG Corporation's experience and extensive contacts in the Japanese life sciences and toxicology sectors will help to further develop our customer base in this important market," said commercial director at Gentronix, Steve Beasley.